These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 24696843)

  • 1. Expression of EpCAM increases in the hepatitis B related and the treatment-resistant hepatocellular carcinoma.
    Kimura O; Kondo Y; Kogure T; Kakazu E; Ninomiya M; Iwata T; Morosawa T; Shimosegawa T
    Biomed Res Int; 2014; 2014():172913. PubMed ID: 24696843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discrete nature of EpCAM+ and CD90+ cancer stem cells in human hepatocellular carcinoma.
    Yamashita T; Honda M; Nakamoto Y; Baba M; Nio K; Hara Y; Zeng SS; Hayashi T; Kondo M; Takatori H; Yamashita T; Mizukoshi E; Ikeda H; Zen Y; Takamura H; Wang XW; Kaneko S
    Hepatology; 2013 Apr; 57(4):1484-97. PubMed ID: 23174907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features.
    Yamashita T; Ji J; Budhu A; Forgues M; Yang W; Wang HY; Jia H; Ye Q; Qin LX; Wauthier E; Reid LM; Minato H; Honda M; Kaneko S; Tang ZY; Wang XW
    Gastroenterology; 2009 Mar; 136(3):1012-24. PubMed ID: 19150350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression and role of epithelial cell adhesion molecule in dysplastic nodule and hepatocellular carcinoma.
    Bae JS; Noh SJ; Jang KY; Park HS; Chung MJ; Park CK; Moon WS
    Int J Oncol; 2012 Dec; 41(6):2150-8. PubMed ID: 22993038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma.
    Terris B; Cavard C; Perret C
    J Hepatol; 2010 Feb; 52(2):280-1. PubMed ID: 20006402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection.
    Sun YF; Xu Y; Yang XR; Guo W; Zhang X; Qiu SJ; Shi RY; Hu B; Zhou J; Fan J
    Hepatology; 2013 Apr; 57(4):1458-68. PubMed ID: 23175471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of stem cell marker expression on recurrence of TACE-treated hepatocellular carcinoma post liver transplantation.
    Zeng Z; Ren J; O'Neil M; Zhao J; Bridges B; Cox J; Abdulkarim B; Schmitt TM; Kumer SC; Weinman SA
    BMC Cancer; 2012 Dec; 12():584. PubMed ID: 23216644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatic progenitor cells in liver cancers from Asian children.
    Ward SC; Thung SN; Lim KH; Tran TT; Hong TK; Hoang PL; Jang JJ; Park YN; Abe K
    Liver Int; 2010 Jan; 30(1):102-11. PubMed ID: 19793197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncostatin m renders epithelial cell adhesion molecule-positive liver cancer stem cells sensitive to 5-Fluorouracil by inducing hepatocytic differentiation.
    Yamashita T; Honda M; Nio K; Nakamoto Y; Yamashita T; Takamura H; Tani T; Zen Y; Kaneko S
    Cancer Res; 2010 Jun; 70(11):4687-97. PubMed ID: 20484035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer stem cell markers correlate with early recurrence and survival in hepatocellular carcinoma.
    Guo Z; Li LQ; Jiang JH; Ou C; Zeng LX; Xiang BD
    World J Gastroenterol; 2014 Feb; 20(8):2098-106. PubMed ID: 24616575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EpCAM-high liver cancer stem cells resist natural killer cell-mediated cytotoxicity by upregulating CEACAM1.
    Park DJ; Sung PS; Kim JH; Lee GW; Jang JW; Jung ES; Bae SH; Choi JY; Yoon SK
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32221015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-throughput screening for identification of inhibitors of EpCAM-dependent growth of hepatocellular carcinoma cells.
    Henrich CJ; Budhu A; Yu Z; Evans JR; Goncharova EI; Ransom TT; Wang XW; McMahon JB
    Chem Biol Drug Des; 2013 Aug; 82(2):131-9. PubMed ID: 23879724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Childhood hepatocellular carcinoma: a clinicopathological study of 12 cases with special reference to EpCAM.
    Zen Y; Vara R; Portmann B; Hadzic N
    Histopathology; 2014 Apr; 64(5):671-82. PubMed ID: 24138022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of microRNAs specific for epithelial cell adhesion molecule-positive tumor cells in hepatocellular carcinoma.
    Ji J; Zheng X; Forgues M; Yamashita T; Wauthier EL; Reid LM; Wen X; Song Y; Wei JS; Khan J; Thorgeirsson SS; Wang XW
    Hepatology; 2015 Sep; 62(3):829-40. PubMed ID: 25953724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis B virus X protein induces EpCAM expression via active DNA demethylation directed by RelA in complex with EZH2 and TET2.
    Fan H; Zhang H; Pascuzzi PE; Andrisani O
    Oncogene; 2016 Feb; 35(6):715-26. PubMed ID: 25893293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer stem cells in hepatocellular carcinoma--an immunohistochemical study with histopathological association.
    Matthai SM; Ramakrishna B
    Indian J Med Res; 2015 Oct; 142(4):391-8. PubMed ID: 26609030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Branched chain amino acid suppresses hepatocellular cancer stem cells through the activation of mammalian target of rapamycin.
    Nishitani S; Horie M; Ishizaki S; Yano H
    PLoS One; 2013; 8(11):e82346. PubMed ID: 24312415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High expression of MAGE-A9 contributes to stemness and malignancy of human hepatocellular carcinoma.
    Wei Y; Wang Y; Gong J; Rao L; Wu Z; Nie T; Shi D; Zhang L
    Int J Oncol; 2018 Jan; 52(1):219-230. PubMed ID: 29138811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does the hepatitis B antigen HBx promote the appearance of liver cancer stem cells?
    Arzumanyan A; Friedman T; Ng IO; Clayton MM; Lian Z; Feitelson MA
    Cancer Res; 2011 May; 71(10):3701-8. PubMed ID: 21464043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peritumoral EpCAM Is an Independent Prognostic Marker after Curative Resection of HBV-Related Hepatocellular Carcinoma.
    Dai XM; Huang T; Yang SL; Zheng XM; Chen GG; Zhang T
    Dis Markers; 2017; 2017():8495326. PubMed ID: 28572700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.